Xcout Intel
Precision Biologics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Precision Biologics, Inc. among biotechnology companies — ranked by similarity to what Precision Biologics, Inc. actually does, not by market-cap band.
Subscribe to see Precision Biologics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Precision Biologics, Inc.
Precision Biologics, Inc. is a biotechnology research company headquartered in Bethesda, Maryland, focused on developing monoclonal antibodies targeted against specific tumor antigens.
Precision Biologics, Inc. at a glance
Precision Biologics, Inc. is a biotechnology company headquartered in United States. Its most recent funding round raised $53.1M in October 2015. Xcout tracks 8 named people at Precision Biologics, Inc., including PHILIP ARLEN (President and CEO).
Precision Biologics, Inc. leadership
- PHILIP ARLENPresident and CEO
- Stanley B. Archibald, Jr.Chairman of the Board
- Adam S. MostafaBoard Member
- Christina M. AnnunziataBoard Member
- Christopher HyunBoard Member
- Jim FeldmanBoard Member
2 more named people on record for Precision Biologics, Inc., with roles, board committees and tenure — see the full roster →
Precision Biologics, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $53.1M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Precision Biologics, Inc. competitors
Ranked by semantic similarity — how close each company is to Precision Biologics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Life Sciences
Northern Biologics is a biotechnology company developing antibody-based therapeutics, with a focus on treating cancer and targeting the tumor microenvironment. Its products are intended for oncology patients and clinical partners in the biopharmaceutical sector.
Similar biotechnology company
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfolio also encompasses Ex vivo Allogeneic CAR T Immunotherapy, an innovative approach where specific immune cells, known as T-cells, are genetically modified outside the body to precisely identify and eliminate cancer cells. Among its prominent therapeutic candidates are: PBCAR0191, currently undergoing Phase 1/2a clinical trials for adult patients battling relapsed/refractory (R/R) non-Hodgkin lymphoma or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL). PBCAR19B, an anti-CD19 CAR T candidate leveraging a "stealth cell" platform through a single-step gene edit, engineered to reduce the likelihood of chromosomal abnormalities. PBCAR269A, an investigational allogeneic CAR T immunotherapy formulated to target BCMA, intended for the treatment of R/R multiple myeloma. Precision BioSciences has strategically formed several collaborative alliances. These include an agreement with Les Laboratoires Servier for the development and commercialization of allogeneic chimeric antigen receptor T-cell therapies, aimed at various antigen targets, including hematological cancers beyond CD19, and solid tumors. The company is also partnering with Tiziana Life Sciences to assess foralumab, a fully human anti-CD3 monoclonal antibody, for its utility as a lymphodepleting agent in potential cancer treatments. Furthermore, a collaboration with iECURE, Inc. focuses on advancing ARCUS-based gene editing therapies. Established in 2006, Precision BioSciences, Inc. maintains its corporate headquarters in Durham, North Carolina.
Biotech
HiFiBio Therapeutics is a clinical-stage immune modulation biotechnology company headquartered in Cambridge, Massachusetts. The company focuses on discovering and developing novel precision antibody therapeutics for immunology and oncology applications.
Biotech
Deka Biosciences, Inc. is an early-stage biotechnology holding company located in Germantown, Maryland, focused on developing and delivering life-changing medicines for cancer patients.
Biotech
Northwest Biotherapeutics, Inc. (NWBO) is a biotechnology firm that creates personalized immune-based treatments for various cancers, operating both within the United States and internationally. Their product pipeline relies on DCVax, a proprietary technology platform. This platform harnesses a patient's own activated dendritic cells to stimulate their immune system to combat cancerous cells. The company's leading therapeutic candidate, DCVax-L, has successfully completed Phase III clinical trials targeting Glioblastoma multiforme, an aggressive form of brain cancer. Additionally, Northwest Biotherapeutics is progressing DCVax-Direct through Phase I/II clinical studies, focusing on the treatment of inoperable solid tumors. Founded in 1996, the company's headquarters are situated in Bethesda, Maryland.
Similar biotechnology company
Prellis Biologics, Inc. is a privately held biotechnology company headquartered in Berkeley, California, within the San Francisco Bay Area. It develops human antibody therapeutics and focuses on antibody discovery leveraging AI and immune diversity.
Similar biotechnology company
Perseus Proteomics Inc. is a Japanese biotechnology company focused on antibody drug discovery and research support. The firm develops novel therapeutic antibody drugs for cancer and other diseases utilizing its proprietary antibody technologies.
Similar biotechnology company
Arcellx, Inc. is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, dedicated to developing innovative immunotherapies and cell therapies for cancer patients.
Similar biotechnology company
ImaginAb, Inc. is a global biotechnology company headquartered in California, with operations in Los Angeles and San Diego. It focuses on developing next-generation imaging and radiopharmaceutical products for cancer immunology.
Similar biotechnology company
AbelZeta is a global clinical-stage biopharmaceutical company pioneering T cell-based therapies targeting cancer, inflammation, and immunological issues, with centers in Rockville, Maryland and Shanghai, China.
Similar biotechnology company
Prince Biotech, Inc. is a biotechnology company that researches and develops immunotherapy and regenerative medicine treatments based on Preimplantation Factor (PIF) and its synthetic analog, sPIF. The company focuses on addressing unmet medical needs in areas such as autoimmune diseases, traumatic brain injury, acute radiation syndrome, stroke, and reproductive medicine through diagnostic tests designed to improve IVF success rates.
Biotech
Philogen is a Swiss-Italian biotechnology company that focuses on the research, development, and commercialization of targeted therapeutics for the treatment of cancer and other serious conditions. The company utilizes proprietary antibody-based technologies to develop biopharmaceuticals, immunotherapies, and radio-conjugates for oncology and imaging applications.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Precision Biologics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Precision Biologics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →